Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kymera Therapeutics Inc
KYMR | US
84.91
USD-2.26
-2.59%
KYMR | US
Loading StockChartView...
About Kymera Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
84.91
Open
88.00
High
88.00
Low
84.49
Kymera Therapeutics Inc. a biopharmaceutical company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program which is in Phase I clinical trial for the treatment of immunology-inflammation diseases including hidradenitis suppurativa atopic dermatitis macrophage activation syndrome general pustular psoriasis and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown Massachusetts.
View LessKYMR | US
Risk
38.9
Sharpe
2.23
Luna's Score
55/100
Recommendation
Hold
Luna says (KYMR | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
36.6%1 month
38.9%3 months
40.2%6 months
72.2%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.36
Debt to equity
0.13
Debt to assets
0.11
Ent. to EBITDA
-9.49
Ent. to rev.
28.97
PEG
-
Other Fundamentals
EBITDA
-176.97M
MarketCap
5.48B
MarketCap(USD)
5.48B
Div. yield
-
Op. margin
-198.54
Erngs. growth
-
Rev. growth
55.30
Ret. on equity
-28.18
Short ratio
19.78
Short perc.
15.23
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
5.95
Range1M
14.44
Range3M
27.61
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.67
Price X volume
31.45M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.49 | 0.53 | Cheaper |
| Ent. to Revenue | 28.97 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.36 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 40.18 | 72.80 | Lower Risk |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.11 | 0.25 | Cheaper |
| Market Cap | 5.48B | 3.66B | Market Leader |
